Ravi & Swati’s Story

Share On:


Ravi and Swati, a non-consanguineous couple, lost their child on the 52nd day of life. The infant was suspected of having Maple Syrup Urine Disease (MSUD), an inherited metabolic disorder in which the body is unable to properly break down certain amino acids. This leads to a build-up of toxic substances in the blood, resulting in severe neurological complications that can be life-threatening.

Unfortunately, the condition could not be confirmed through further investigations due to the child’s early demise. The couple was subsequently advised to undergo genetic carrier screening to determine whether a hereditary mutation was present.

Genetic analysis revealed that both parents were carriers of a pathogenic mutation in the DBT gene, which is associated with MSUD. During their next pregnancy, the couple opted for prenatal diagnosis through chorionic villus sampling (CVS) at 12–13 weeks of gestation. The results showed that the fetus had not inherited the parental mutations and was therefore unaffected.

The couple continued the pregnancy and successfully avoided the recurrence of the disorder. This case highlights the critical role of carrier screening and targeted prenatal testing in preventing genetic disorders in future pregnancies.

Summary

  • Carrier screening helped identify a pathogenic mutation in the DBT gene in both parents.
  • Subsequent prenatal testing of the fetus confirmed the absence of the mutation, thereby preventing the birth of another child affected by the same disorder.


About MedGenome

MedGenome offers the most accurate non-invasive prenatal screening test (NIPT), genetic carrier screening, preimplantation genetic screening/diagnosis (PGS/PGD) and product of conception testing. Additionally, MedGenome offers on-demand pre- and post-test genetic counselling to all patients.

MedGenome Claria Offers Test Sample RequirementsRequired Forms TAT
Carrier screening panel package:
  • Silver-200 genes
  • Gold-500 genes
  • Platinum-Over 2000 genes
  • MLPA(SMN,DMD,CYP21A2)

3ml peripheral blood in EDTA vacutainer or 1 microgram of purified genomic DNA.
Relevant clinical information, including all the clinical presentations and symptoms.21 to 28 days

Related Articles

Ramdev and Savita’s Fight Against Thalassemia

June 25, 2021

Arjun’s Battle with Leukemia

December 2, 2022

Early Detection of CAD in 14-Year-Old

November 22, 2024

More about Medgenome

MedGenome offers highly accurate genetic testing services, including Non-Invasive Prenatal Testing (NIPT), Genetic Carrier Screening, Preimplantation Genetic Screening and Diagnosis (PGS/PGD), as well as Product of Conception (POC) testing. In addition, MedGenome provides on-demand genetic counselling both before and after testing for all patients.

Medgenome Offers

Preimplantation Genetic Screening

Test Sample Requirements

Day 5 (few cells) embryon biopsy or Day3 (single cell)

Required Forms

Informed Consent Form & Test Requisition Form

TAT

7 working days